中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study

文献类型：期刊论文

作者Wang, Wenxian2,3; Gu, Xiaodong2,3; Wang, Liping4; Pu, Xingxiang5; Feng, Huijing6; Xu, Chunwei7; Lou, Guangyuan2,3; Shao, Lan2,3; Xu, Yibing2,3; Wang, Qian8
刊名CANCER IMMUNOLOGY IMMUNOTHERAPY
出版日期2021-11-24
关键词Non-small cell lung cancer PD-L1 Immune checkpoint inhibitor Immune-related adverse event
ISSN号0340-7004
DOI10.1007/s00262-021-03115-y
通讯作者Song, Zhengbo(zheng_bo_song@163.com)
英文摘要Patients treated with immune checkpoint inhibitors (ICIs) often experience unique immune-related adverse events (irAEs), and the previous studies demonstrated an association between irAEs and better outcomes in patients with ICI treatment for advanced non-small cell lung cancer (NSCLC). However, the correlation between the occurrence of mild and severe irAEs and prognosis remains unclear. Additionally, little is known regarding the association between the timing of mild and severe irAEs and clinical outcomes. We retrospectively conducted a multicenter study of advanced NSCLC patients treated with ICI monotherapy. Of the 222 patients, 79 patients (35.6%) experienced at least one irAE, and most were of grade 1 or 2 (mild) (26.6%). The most common irAEs were pneumonitis (n = 21, 9.5%) and skin-related adverse reactions (n = 19, 8.6%). The median progression-free survival of all patients treated with ICIs was 3.2 months. Patients experiencing irAEs had a better prognosis than those without such events (6.5 vs. 2.6 months, p = 0.004), and mild irAEs were associated with the best prognosis. The difference in overall survival between mild and severe irAEs was significant (34.3 vs. 17.3 months, p = 0.021). We further analyzed differences between patients with irAEs occurring at 3 or 6 weeks, and found that the earlier the occurrence of mild irAEs, the better the prognosis; however, the opposite was true for severe irAEs. In summary, patients with early occurring mild irAEs showed better clinical outcomes, whereas those with early severe irAEs tended to show poorer clinical outcomes.
WOS关键词NIVOLUMAB ; ASSOCIATION ; DOCETAXEL ; IPILIMUMAB ; EFFICACY
资助项目Zhejiang Chinese Medical Science and Technology Foundation[2021ZQ013] ; Xisike-Hanson Cancer Research Foundation[Y-HS2019-20] ; Basic Discipline Layout Project of Shenzhen City[JCYJ20170818110544730] ; Sanming Project of Medicine in Shenzhen[SZSM 201801060]
WOS研究方向Oncology ; Immunology
语种英语
WOS记录号WOS:000722115000002
出版者SPRINGER
资助机构Zhejiang Chinese Medical Science and Technology Foundation ; Xisike-Hanson Cancer Research Foundation ; Basic Discipline Layout Project of Shenzhen City ; Sanming Project of Medicine in Shenzhen
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/126612]  
专题中国科学院合肥物质科学研究院
通讯作者Song, Zhengbo
作者单位1.ShenZhen Univ Hlth Sci Ctr, Shenzhen 518001, Guangdong, Peoples R China
2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, 1 Banshan East St, Hangzhou 310022, Zhejiang, Peoples R China
3.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou 310022, Zhejiang, Peoples R China
4.Baotou Canc Hosp, Dept Oncol, Baotou 014000, Inner Mongolia, Peoples R China
5.Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med,Dept Med Oncol, Changsha 410013, Hunan, Peoples R China
6.Shanxi Acad Med Sci, Shanxi Bethune Hosp, Dept Thorac Oncol, Taiyuan 030032, Shanxi, Peoples R China
7.Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210002, Jiangsu, Peoples R China
8.Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Resp Med, Affiliated Hosp, Nanjing 210029, Jiangsu, Peoples R China
9.ShenZhen Univ, Dept Oncol, Affiliated Hosp 3, Shenzhen 518001, Guangdong, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Wenxian,Gu, Xiaodong,Wang, Liping,et al. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY,2021.
APA Wang, Wenxian.,Gu, Xiaodong.,Wang, Liping.,Pu, Xingxiang.,Feng, Huijing.,...&Song, Zhengbo.(2021).The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.CANCER IMMUNOLOGY IMMUNOTHERAPY.
MLA Wang, Wenxian,et al."The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study".CANCER IMMUNOLOGY IMMUNOTHERAPY (2021).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。